These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

385 related items for PubMed ID: 16507128

  • 1. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period.
    Gomez-Reino JJ, Carmona L, BIOBADASER Group.
    Arthritis Res Ther; 2006; 8(1):R29. PubMed ID: 16507128
    [Abstract] [Full Text] [Related]

  • 2. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, British Society for Rheumatology Biologics Register.
    Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
    [Abstract] [Full Text] [Related]

  • 3. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [Abstract] [Full Text] [Related]

  • 4. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M, Fox KM, Watson C, Princic N, Gandra SR.
    Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
    [Abstract] [Full Text] [Related]

  • 5. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
    Conti F, Ceccarelli F, Marocchi E, Magrini L, Spinelli FR, Spadaro A, Scrivo R, Valesini G.
    Ann Rheum Dis; 2007 Oct; 66(10):1393-7. PubMed ID: 17613555
    [Abstract] [Full Text] [Related]

  • 6. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register.
    Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P.
    Arthritis Care Res (Hoboken); 2010 Oct; 62(10):1362-9. PubMed ID: 20506310
    [Abstract] [Full Text] [Related]

  • 7. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS, Koldingsnes W, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.
    Arthritis Rheum; 2008 Feb 15; 59(2):234-40. PubMed ID: 18240258
    [Abstract] [Full Text] [Related]

  • 8. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P, Vähäsalo P, Honkanen V, Lahdenne P.
    Ann Rheum Dis; 2009 Apr 15; 68(4):552-7. PubMed ID: 18467515
    [Abstract] [Full Text] [Related]

  • 9. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice.
    Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, Caporali R, Bobbio-Pallavicini F, Favalli EG.
    Ann N Y Acad Sci; 2009 Sep 15; 1173():837-46. PubMed ID: 19758236
    [Abstract] [Full Text] [Related]

  • 10. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L.
    Arthritis Rheum; 2009 Nov 15; 60(11):3180-9. PubMed ID: 19877027
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.
    JAMA; 2009 Feb 18; 301(7):737-44. PubMed ID: 19224750
    [Abstract] [Full Text] [Related]

  • 13. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I, Markatseli TE, Papagoras C, Voulgari PV, Alamanos Y, Drosos AA.
    Semin Arthritis Rheum; 2011 Apr 18; 40(5):398-406. PubMed ID: 20843542
    [Abstract] [Full Text] [Related]

  • 14. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L, Pope JE, Payne M.
    J Rheumatol; 2009 Jul 18; 36(7):1421-8. PubMed ID: 19487267
    [Abstract] [Full Text] [Related]

  • 15. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
    Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM.
    Adv Ther; 2012 Mar 18; 29(3):234-48. PubMed ID: 22411424
    [Abstract] [Full Text] [Related]

  • 16. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA, Klingman D, Hazard E, Ray S.
    Clin Ther; 2009 Apr 18; 31(4):825-35. PubMed ID: 19446156
    [Abstract] [Full Text] [Related]

  • 17. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
    Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF.
    Scand J Rheumatol; 2005 Apr 18; 34(5):353-8. PubMed ID: 16234182
    [Abstract] [Full Text] [Related]

  • 18. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
    Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M, REAL Study Group.
    J Rheumatol; 2011 Jul 18; 38(7):1258-64. PubMed ID: 21498482
    [Abstract] [Full Text] [Related]

  • 19. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.
    Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A, Swiss Clinical Quality Management Physicians.
    Arthritis Rheum; 2009 May 15; 61(5):560-8. PubMed ID: 19405000
    [Abstract] [Full Text] [Related]

  • 20. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
    van Dartel SA, Fransen J, Kievit W, Flendrie M, den Broeder AA, Visser H, Hartkamp A, van de Laar MA, van Riel PL.
    Ann Rheum Dis; 2013 Jun 15; 72(6):895-900. PubMed ID: 22887849
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.